Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

Keratinocyte cancer Melanoma Prevention Skin cancer UV-protection Ultraviolet radiation

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 15 02 2024
revised: 16 04 2024
accepted: 17 04 2024
medline: 1 5 2024
pubmed: 1 5 2024
entrez: 1 5 2024
Statut: aheadofprint

Résumé

Cancers of the skin are the most commonly occurring cancers in humans. In fair-skinned populations, up to 95% of keratinocyte skin cancers and 70-95% of cutaneous melanomas are caused by ultraviolet radiation and are thus theoretically preventable. Currently, however, there is no comprehensive global advice on practical steps to be taken to reduce the toll of skin cancer. To address this gap, an expert working group comprising clinicians and researchers from Africa, America, Asia, Australia, and Europe, together with learned societies (European Association of Dermato-Oncology, Euromelanoma, Euroskin, European Union of Medical Specialists, and the Melanoma World Society) reviewed the extant evidence and issued the following evidence-based recommendations for photoprotection as a strategy to prevent skin cancer. Fair skinned people, especially children, should minimise their exposure to ultraviolet radiation, and are advised to use protective measures when the UV index is forecast to reach 3 or higher. Protective measures include a combination of seeking shade, physical protection (e.g. clothing, hat, sunglasses), and applying broad-spectrum, SPF 30 + sunscreens to uncovered skin. Intentional exposure to solar ultraviolet radiation for the purpose of sunbathing and tanning is considered an unhealthy behaviour and should be avoided. Similarly, use of solaria and other artificial sources of ultraviolet radiation to encourage tanning should be strongly discouraged, through regulation if necessary. Primary prevention of skin cancer has a positive return on investment. We encourage policymakers to communicate these messages to the general public and promote their wider implementation.

Identifiants

pubmed: 38691877
pii: S0959-8049(24)00730-5
doi: 10.1016/j.ejca.2024.114074
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114074

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.

Auteurs

Claus Garbe (C)

Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Electronic address: claus.garbe@med.uni-tuebingen.de.

Ana-Maria Forsea (AM)

Dermatology Department, Elias University Hospital, Carol Davila University of Medicine and Pharmacy Bucharest, Romania.

Teresa Amaral (T)

Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.

Petr Arenberger (P)

Department of Dermatovenereology, Charles University Third Medical Faculty and University Hospital Kralovske Vinohrady, Prague, Czech Republic.

Philippe Autier (P)

International Prevention Research Institute (i-PRI), Dardilly, France.

Marianne Berwick (M)

University of New Mexico Comprehensive Cancer Centre, Albuquerque, USA.

Brigitta Boonen (B)

Belgian Cancer foundation, Brussels, Belgium.

Matilda Bylaite (M)

Faculty of Medicine, Centre of Dermatovenereology, Clinic of Infectious Diseases and Dermatovenereology, Vilnius University, Vilnius, Lithuania.

Veronique Del Marmol (V)

Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Brigitte Dreno (B)

France Nantes University, Inserm 1302, INCIT, F-44000 Nantes, France.

Maria Concetta Fargnoli (MC)

Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.

Alan C Geller (AC)

Department of Social and Behavioural Sciences, Public Health Campus, Boston, MA, USA.

Adele C Green (AC)

Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Rüdiger Greinert (R)

Skin Cancer Centre, Laboratory for Molecular Cell Biology, Elbe Hospital Buxtehude, Buxtehude, Germany.

Axel Hauschild (A)

Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Catherine A Harwood (CA)

Department of Dermatology, Barts Health NHS Trust and Centre for Cell Biology and Cutaneous Research Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK.

Isabelle Hoorens (I)

Department of Dermatology, Ghent University Hospital, Ghent, Belgium.

Lidija Kandolf (L)

Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.

Roland Kaufmann (R)

Department of Dermatology, Venerology and Allergology, Frankfurt University Hospital, Frankfurt, Germany.

Nicole Kelleners-Smeets (N)

GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Dermatology, Maastricht UMC+ Comprehensive Cancer Centre, Maastricht, the Netherlands.

Aimilios Lallas (A)

First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.

Celeste Lebbé (C)

Université Paris Cite, AP-HP Dermato-oncology and CIC, Cancer institute APHP. Nord Paris Cité, France; INSERM U976, Saint Louis Hospital, Paris, France.

Ulrike Leiter (U)

Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany.

Henry W Lim (HW)

Department of Dermatology, Henry Ford Health, Detroit, MI, USA.

Caterina Longo (C)

Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy; Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Skin Cancer Centre, Reggio Emilia, Italy.

Joseph Malvehy (J)

Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain.

David Moreno (D)

Medical-&-Surgical Dermatology Service. Hospital Universitario Virgen Macarena, Sevilla, Spain.

Giovanni Pellacani (G)

Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.

Ketty Peris (K)

Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.

Caroline Robert (C)

Department of Medical Oncology, Gustave Roussy and Paris Saclay University, Villejuif, France.

Philippe Saiag (P)

Department of General and Oncologic Dermatology, Ambroise Paré hospital, APHP, & EA 4340 "Biomarkers in cancerology and haematooncology", UVSQ, Université Paris-Saclay, 92104 Boulogne-Billancourt, France.

Dirk Schadendorf (D)

Department of Dermatology & West German Cancer Centre, University Hospital Essen & German Cancer Consortium, Campus Essen & National Centre for tumour Diseases (NCT)-West, Campus Essen, Germany.

H Peter Soyer (H)

Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Queensland, Australia.

Eggert Stockfleth (E)

Department of Dermatology, Ruhr-University, Bochum, Bochum, Germany.

Alex Stratigos (A)

First Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital, Athens, Greece.

Hisashi Uhara (H)

Department of Dermatology, Sapporo Medical University, Sapporo, Japan.

Ricardo Vieira (R)

Department of Dermatology and Venereology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.

Beate Volkmer (B)

Skin Cancer Centre, Laboratory for Molecular Cell Biology, Elbe Hospital Buxtehude, Buxtehude, Germany.

Martin A Weinstock (MA)

Brown University and V A Medical Centre, Providence, RI, USA.

Dagmar Whitaker (D)

Private Practice, Cape Town, South Africa.

Iris Zalaudek (I)

Department of Dermatology and Venereology of the Hospital Clinics Giuliano Isontino (ASUGI), Maggiore Hospital, Trieste, Italy.

David C Whiteman (DC)

Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Lieve Brochez (L)

Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.

Classifications MeSH